Metagenomi (MGX) to Release Quarterly Earnings on Wednesday

Metagenomi (NASDAQ:MGX) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Metagenomi to post earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). The firm had revenue of $3.91 million during the quarter, compared to the consensus estimate of $7.33 million. Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Down 4.2%

Shares of NASDAQ MGX opened at $1.27 on Tuesday. The stock’s 50-day simple moving average is $1.52 and its two-hundred day simple moving average is $1.88. Metagenomi has a twelve month low of $1.23 and a twelve month high of $3.95. The firm has a market capitalization of $47.59 million, a P/E ratio of -0.53 and a beta of 0.45.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MGX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. Wall Street Zen lowered shares of Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Trading of Metagenomi

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Metagenomi in the 2nd quarter valued at $235,000. Marshall Wace LLP bought a new stake in Metagenomi in the second quarter worth $222,000. Wells Fargo & Company MN boosted its position in Metagenomi by 16.1% during the fourth quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock valued at $192,000 after buying an additional 16,402 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Metagenomi by 4,155.7% during the third quarter. JPMorgan Chase & Co. now owns 62,559 shares of the company’s stock valued at $148,000 after buying an additional 61,089 shares during the last quarter. Finally, Man Group plc bought a new position in shares of Metagenomi during the third quarter valued at about $125,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.